FARO is Taking Care of the Healthcare of Dentists and Patients With the Solar Spectrum LED Technology – SunLike – From Seoul Semiconductor
From a research study 30% of dentists will suffer from visual reduction capabilities in the next 30 years. For FARO, the solutions are already here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005033/en/
Fig.1 SunLike CRI values for 6500K (Daylight) (Graphic: Business Wire)
With the new dentist lamp Eva and the new ceiling panel Siderea equipped with SunLike LED technology, the historical and global market leader in the orthodontist equipment sector FARO wants to keep demonstrating their technological leadership and implement the latest technology available that can improve the healthcare of the users.
FARO has developed 2 new products with edge technology that will improve patients and doctors' lives, as new products include solar spectrum light that will help on concentration, relax and recovery activities as demonstrated by recent studies done by University of Basel and Harvard medical school.
The Eva lamp, completely developed, tested and manufactured in FARO headquarters in Ornago, near Milan, represents a technological revolution in the market. After many years of research the reflector is perfectly adapted to the new LED technology obtaining the perfect system combination that brings the best possible light and beam angle to the needed place.
The version Eva Sunlight uses the special SunLike LEDs from Seoul Semiconductor with a solar spectrum at any colour temperature of the light and produces the closest light to the real and natural Sunlight.
With an illumination of 50.000 lux the Eva luminaire can guide the professionals to see all the smallest details in their day to day operations and guarantee at the same time the maximum visual comfort for the patient and the dentist.
Talking about technical parameters the new luminaire is achieving the greatest quality of the light with a CRI of 97 and a TM30 of 100 that brings a perfect vision and colour reproduction of the oral cavities.
To get immediate feedback on the lighting level in use, you just have to take a look at the headlamp; it is also possible to manage all the functions from smartphones and tablets using the app FARO Tech that is available in all app stores.
Finally, Eva has an integrated camera (Eva Cam) which allows you to photograph and video record footage in FHD or even 4K to broadcast live or share images later on.
Siderea Sunlight is the natural complement of the Eva lamp. With the Theia Tech – the special lamp that talks with the intensive light – reducing the stress of the pre-operation for patients.
This combination of Siderea and Eva forms the FARO light system that has been developed to guarantee the ideal conditions for developing the dentists' work.
Siderea is the only dentist panel in the market with technology SunLike that mimics the effects of the natural light with a uniform, multidirectional and proportional light and it deletes all the shadows from traditional lamps. Reassuring the wellbeing and visual effects to operate in the perfect ambient.
“To improve people lives: this is our inspiration as entrepreneurs” explains Cristina Cesari, General Manager of FARO that today counts more than 700 customers, with products installed in more than 70 countries around the world.
“To reproduce the natural light is our main research driver and is a challenge of great fascination. Today we can bring the benefits of Seoul Semiconductor SunLike technology into the health medical area and improve all professional environments” added Cristina Cesari.
Oliver Schaefer, Executive Vice-president for Seoul Semiconductor Europe said “We are very honoured and proud to be part of the new FARO products with our latest LED technology SunLike that brings the Sun benefits to indoor spaces”.
FARO is an historic Italian brand for lighting in the dental sector. FARO stands for high Italian quality, creativity and innovation. We provide products and “lighting systems” to improve the “light experience” because light is not only seen, but above all life and well-being. We are an enthusiastic company serving demanding and visionary customers. In FARO we provide cutting-edge technologies that are considered industry benchmarks, we work enthusiastically to go beyond the boundaries of research to enable the next generation of professional lighting.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike, WICOP, NanoDriver and nPola as examples.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Tel: +39 039 68781
Tel: +49 89 450 36 90
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
causaLens Raises $45m Series A to Scale Human-centered AI That Understands Cause-and-effect28.1.2022 15:46:00 CET | Press release
causaLens, the London deep tech company delivering the future of AI, has raised a $45m Series A round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220126005888/en/ The causaLens co-founders, Dr. Maksim Sipos, CTO, on the left, and Dr. Darko Matovski, CEO, on the right. (Photo: Business Wire) causaLens is the pioneer of Causal AI - the only AI technology quantifying cause-and-effect relationships to reason alongside humans in a manner that is trustworthy, explainable, and fair. Causal AI represents a giant leap ahead of current correlation-based AI technologies, which blindly extrapolate historical data and are unable to ask counterfactual questions — the ‘what ifs’ at the core of human imagination and creativity. causaLens’s no-code platform delivers far more accurate and reliable results, and allows humans and machines to work together for the first time. It is trusted by decision makers across finance, industry, technol
Monrol Signing Agreement to License its GMP Grade Lu-177 n.c.a Production Technology to Curium28.1.2022 13:47:00 CET | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced it has signed an agreement with Curium Netherlands B.V (Curium) to license its GMP grade medical radioisotope, no-carrier-added 177Lu (n.c.a. 177Lu) cutting-edge production technology LuMagic®. This agreement will enable transfer of relevant equipment and supply from Monrol to Curium. Monrol is one of the few producers of Lutetium-177 n.c.a worldwide, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability. Curium planning to manufacture the product Lu-177 n.c.a in its Petten production facility, Netherlands. This licence is offering significant opportunities both for Curium; one of the world’s largest nuclear medicine companies and Monrol; a company which develops, manufactures, and distributes world-class radiopharmaceutical products, radioisotopes to improve qu
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction28.1.2022 13:26:00 CET | Press release
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending Jardiance® (empagliflozin) for the treatment of adults with symptomatic chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced today.1 Empagliflozin was previously approved for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).4 If approved, the positive opinion would expand this indication to be applicable for adults across the full spectrum of left ventricular ejection fraction (LVEF), including preserved ejection fraction (HFpEF). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005861/en/ “For the very first time, we now have a treatment that will improve clinical results across the full spectrum of heart failure patients – regardless of ejection fraction,” said Professor Stefan Anker, Heart Failure Car
Schlumberger DELFI Digital Platform Selected by Northern Lights JV for CO 2 Project28.1.2022 13:00:00 CET | Press release
Schlumberger will deploy the DELFI* cognitive E&P environment on the Norwegian CO2 project by the Northern Lights Joint Venture (NL), to streamline subsurface workflows and longer-term modeling and surveillance of CO2 sequestration. NL was established to develop the world’s first open-source CO2 transport and storage infrastructure, providing accelerated decarbonization opportunities for European industries, with an ambition to store up to 5 million tonnes of CO2 per year based on market demand. For CO2 transportation and storage, Schlumberger digital solutions are used for subsurface characterization and dynamic reservoir simulation, which are key to understanding storage site capacity and the potential for injecting and containing fluids. They are also used for development planning, operations, appraisals, and monitoring purposes. “Northern Lights has recognized the huge potential of Schlumberger’s digital technology to fast-track decision making and de-risk CO2 transportation and st
Pixis Appoints Neel Pandya as the CEO for Europe Business, in Addition to APAC28.1.2022 12:28:00 CET | Press release
Pixis (formerly known as Pyxis One), a leading provider of contextual codeless AI infrastructure for complete marketing optimization, today appointed Neel Pandya as the Chief Executive Officer of its operations in Europe, in addition to his responsibilities of leading the APAC business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220128005166/en/ Neel Pandya joined Pixis as the CEO of APAC in its Bengaluru office after exiting L'Oréal. (Photo: Business Wire) Neel joined Pixis in its Bengaluru office in July 2021 as the CEO of APAC, bringing immense change and progress to the way Pixis operates, and greatly streamlining expansions in the APAC region. Under his leadership, Pixis witnessed a 185% growth in revenue in the APAC region, with India independently recording a 150% of growth. Over the last 7 months, in addition to greatly stabilizing customer churn Neel has also been instrumental in adding close to 30 new enterpris
'True Stories of Investing' - flatexDEGIRO drives financial education with high-quality documentation28.1.2022 10:48:00 CET | Press release
With "True Stories of Investing", flatexDEGIRO AG (WKN: FTG111, ISIN: DE000FTG1111, Ticker: FTK.GR), Europe's largest and fastest-growing retail online broker collaborates with award-winning documentary maker, New Amsterdam, and Discovery, to demystify investing. The documentary premieres on Discovery's channels across Europe starting this weekend and showcases important lessons every retail investor needs to know. In four episodes, renowned journalists, professors, behavioral scientists and investors challenge some of the biggest misconceptions about investing by examining historical events and the mechanisms at work. Frank Niehage, CEO of flatexDEGIRO: "It is our mission to retailise capital markets and empower private individuals to invest in a self-determined and sustainable way. As Europe's leading online broker, we feel responsible for making trading more simple, more informed, and more secure for our customers. With this innovative documentary, we take financial education one st
SoftBank Group Announces Management Transition28.1.2022 05:08:00 CET | Press release
SoftBank Group Corp. (“SoftBank”) today announced that the company and Marcelo Claure have mutually agreed to part ways after a successful nine-year partnership. In conjunction with Mr. Claure’s departure, Michel Combes has been appointed as CEO of SoftBank Group International (“SBGI”). In this position, he will oversee SoftBank Group International’s operating and investment portfolio*. Masayoshi Son, Representative Director, Corporate Officer, Chairman & CEO of SoftBank Group Corp., said, “Marcelo has made many contributions to SoftBank during his time here and we thank him for his dedication and wish him continued success in his future endeavors. I have great confidence in Michel Combes and the talented SoftBank team to continue with the great work we have underway at SBGI.” Mr. Claure said, “I will forever be grateful for my experience at SoftBank over the last nine years. I have had the opportunity to collaborate with some of the world’s great executives and entrepreneurs, and tack